Evidence map›Paper›PMID 39028735›Full record

ArticlePloS one2024

High rates of deferring antiretroviral treatment for patients with HIV and substance use disorders: Results from a national sample of HIV physicians in Ukraine.

Taylor D Ottesen, Jeffrey A Wickersham, Juliana C Lawrence, Sergii Antoniak, Oleksandr Zezuilin, Maxim Polonsky, Svitlana Antonyak, Julia Rozanova, Sergii Dvoriak, Iryna Pykalo and 2 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Taylor D OttesenDepartment of Internal Medicine, Section of Infectious Diseases, AIDS Program, Yale School of Medicine, New Haven, Connecticut, United States of America.ORCID 0000-0002-3777-1955
Jeffrey A WickershamDepartment of Internal Medicine, Section of Infectious Diseases, AIDS Program, Yale School of Medicine, New Haven, Connecticut, United States of America.ORCID 0000-0001-7701-9162
Juliana C LawrenceDepartment of Internal Medicine, Section of Infectious Diseases, AIDS Program, Yale School of Medicine, New Haven, Connecticut, United States of America.ORCID 0000-0002-7056-3795
Sergii AntoniakL.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of the National Academy of Medical Science of Ukraine, Kyiv, Ukraine.ORCID 0000-0003-3332-2762
Oleksandr ZezuilinUkrainian Institute on Public Health Policy, Kyiv, Ukraine.
Maxim PolonskyDepartment of Internal Medicine, Section of Infectious Diseases, AIDS Program, Yale School of Medicine, New Haven, Connecticut, United States of America.
Svitlana AntonyakL.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of the National Academy of Medical Science of Ukraine, Kyiv, Ukraine.
Julia RozanovaDepartment of Internal Medicine, Section of Infectious Diseases, AIDS Program, Yale School of Medicine, New Haven, Connecticut, United States of America.
Sergii DvoriakUkrainian Institute on Public Health Policy, Kyiv, Ukraine.
Iryna PykaloUkrainian Institute on Public Health Policy, Kyiv, Ukraine.
Myroslava FilippovychUkrainian Institute on Public Health Policy, Kyiv, Ukraine.
Fredrick L AlticeDepartment of Internal Medicine, Section of Infectious Diseases, AIDS Program, Yale School of Medicine, New Haven, Connecticut, United States of America.

Funding

Research Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5M
Prison Interventions and HIV Prevention CollaborationR01DA029910 · NIDA · YALE UNIVERSITY · PI FREDERICK LEWIS ALTICE · 2010 to 2026
$7.9M
Expanding Medication Assisted Therapy in Ukraine (ExMAT)R01DA033679 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2012 to 2021
$6.4M
Integrating Addiction Treatment and HIV Services into Primary Care Clinics in UkraineR01DA043125 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2016 to 2021
$4.4M
Integrating Treatment for Mental Disorders in Methadone Clinics in UkraineU01DA045384 · NIDA · UKRAINIAN INSTITUTE ON PUBLIC HEALTH POLICY · PI DVORIAK, SERGII · 2018 to 2020
$1.4M
FIC NIH HHS D43 TW010540NIDA NIH HHS R01 DA029910NIDA NIH HHS R01 DA033679NIDA NIH HHS R01 DA043125NIDA NIH HHS U01 DA045384
6 · The paper itself

Abstract

backgroundHIV incidence and mortality are increasing in Ukraine despite their reductions globally, in part due to suboptimal antiretroviral therapy (ART) coverage in key populations of people with HIV (PWH) where the epidemic is concentrated. As physicians are gatekeepers to ART prescription, stigma and discrimination barriers are understudied as a key to meeting HIV treatment targets in key populations.

methodsA national sample (N = 204) of ART-prescribing physicians in Ukraine were surveyed between August and November 2019. Participants underwent a series of randomized, hypothetical HIV clinical scenarios and decided whether to initiate or defer (or withhold) ART. Scenarios varied based on 5 distinct CD4 counts (CD4: 17, 176, 305, 470, or 520 cells/mL) and 10 different PWH key populations. Z scores and McNemar's test for paired samples were used to assess differences between key populations and CD4 count. Feeling thermometers were used to assess stigma-related measures toward key populations among physicians.

resultsPhysicians were highly experienced (mean = 19 years) HIV treaters, female (80.4%), and trained in infectious diseases (76.5%). Patients who drink alcohol (range: 21.6%-23.5%) or use (PWUD range: 16.7%-20.1%) or inject (PWID range: 15.5%-20.1%) drugs were most likely to have ART deferred, even at AIDS-defining CD4 counts. PWID maintained on methadone, however, were significantly (p<0.001) less likely to have ART deferred compared with those who were not (range: 7.8%-12.7%) on methadone. Men who have sex with men (range: 5.4%-10.8%), transgender women (range: 4.9%-11.3%), sex workers (range: 3.9%-10.3%),and having an HIV-uninfected sex partner (range: 3.9%-9.3%) had the lowest likelihood of ART deferral. Increasing levels of stigma (i.e., feeling thermometers) towards a key population was correlated with ART deferral (i.e., discrimination).

conclusionsDespite international and Ukrainian guidelines recommending ART prescription for all PWH, irrespective of risk or CD4 count, ART deferral by experienced HIV experts remains high in certain key populations, especially in PWH and substance use disorders. Strategies that initiate ART immediately after diagnosis (i.e., rapid start antiretroviral therapy), independent of risk group, should be prioritized to truly mitigate the current epidemic.

Indexed as

HIV InfectionsPhysiciansSubstance-Related DisordersAdultAnti-HIV AgentsCD4 Lymphocyte CountFemaleHumansMaleMiddle AgedPractice Patterns, Physicians'Social StigmaSurveys and QuestionnairesUkraineAnti-HIV Agents

Identifiers

PMID39028735
PMCPMC11259278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.